MARGARET STUBNER: Open Payments
NPI 1427569714 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,959 in 87 payments from 19 companies in 2025. Trend: 2023 $1,669 · 2024 $1,294 · 2025 $1,959
Food & beverage: $1,959
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $314 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $285 |
| Janssen Biotech, Inc. | 8 | $278 |
| ABBVIE INC. | 13 | $261 |
| GENZYME CORPORATION | 4 | $131 |
| Ardelyx, Inc. | 4 | $125 |
| Gilead Sciences, Inc. | 4 | $99 |
| Madrigal Pharmaceuticals | 4 | $94 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| Ipsen Biopharmaceuticals, Inc | 3 | $61 |
Products named: XIFAXAN, TREMFYA, ENTYVIO, DUPIXENT, IBSRELA, REZDIFFRA, RINVOQ, LINZESS.
Industry payments across MD — which companies pay providers there.
